A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

Inclusion Criteria:

- Must be over 40 years of age.

- Must have an informant or study partner that can provide independent information of
functioning.

- Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill
criteria for possible PSP, subjects must have a gradually progressive disorder with
either vertical (upward or downward) supranuclear palsy or both slowing of vertical
saccades and prominent postural instability with falls in the first year of disease
onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or
downward gaze) supranuclear palsy and prominent postural instability with falls in the
first year of disease onset.

- Must have symptoms for <4 years.

- Must be able to ambulate independently.

- Must have a PSP rating scale score of less than 40 and a Montreal Cognitive Assessment
score of greater than 20.

Exclusion Criteria:

- Subjects will be excluded if they meet criteria for another neurodegenerative disease
(including corticobasal syndrome, frontotemporal dementia, primary progressive
aphasia, Alzheimer's disease, multiple system atrophy and Parkinson's disease) or do
not have the symptoms necessary to fulfill inclusion criteria for possible PSP.

- Subjects with concurrent illnesses that could account for their symptoms, such as
traumatic brain injury, encephalitis, strokes or developmental syndromes will be
excluded.

- Women that are pregnant or post-partum and breast-feeding will be excluded.

- Subjects will be excluded from the study if they are unable to undergo the tau-PET
scan due to a prolonged QT interval on ECG, or if they have any of the following
genetic conditions which can increase the chance of cancer: Cowden disease, Lynch
syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome.

- Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace
maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may
confound brain imaging studies (e.g. structural abnormalities, including subdural
hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically
unstable or are on medications that might affect brain structure or metabolism (e.g.
chemotherapy).

- Subjects will also be excluded if they do not have an informant, or do not consent to
research.